Catalyst
Monitor results for ctDNA MRD negativity and progression-free survival rates, as well as safety data over the treatment period.
Date
June 19, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.